Umbilical cord blood stem cells: Implications for cardiovascular regenerative medicine

Jonathan L. Goldberg, Mary J. Laughlin, Vincent J. Pompili

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

The treatment of cardiovascular disease has benefited from advances in pharmacologic and intravascular intervention reducing the morbidity and mortality associated with this disease. To address the need in managing clinically complex vascular disease with limited therapeutic options studies have focused on cellular therapy as a means to augment compensatory mechanisms and to potentially prevent escalation and advancement of disease. Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSC) and thus may be a potential source of cells for this type of therapy. UCB can be collected at no risk to the donor, is immediately available, has a wider availability of HLA phenotypes with a possible lower immune reactivity and does not provoke ethically charged debates. Moreover, stem cells isolated from patients with chronic disease have impairment of their reparative abilities thus limiting their therapeutic impact. The potential of UCB HSC in augmenting this process has been studied extensively both in vitro and in vivo and has shown a benefit in acute and chronic vascular ischemia. Although studies suggest efficacy with no obvious safety concerns the mechanism for this therapeutic effect is unknown.

Original languageEnglish (US)
Pages (from-to)912-920
Number of pages9
JournalJournal of Molecular and Cellular Cardiology
Volume42
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Regenerative Medicine
Fetal Blood
Blood Cells
Stem Cells
Hematopoietic Stem Cells
Therapeutic Uses
Therapeutics
Cell- and Tissue-Based Therapy
Vascular Diseases
Blood Vessels
Chronic Disease
Cardiovascular Diseases
Ischemia
Tissue Donors
Morbidity
Phenotype
Safety
Mortality

Keywords

  • Angiogenesis
  • Cardiovascular disease
  • Hematopoietic stem cell
  • Regenerative medicine
  • Umbilical cord blood

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Umbilical cord blood stem cells : Implications for cardiovascular regenerative medicine. / Goldberg, Jonathan L.; Laughlin, Mary J.; Pompili, Vincent J.

In: Journal of Molecular and Cellular Cardiology, Vol. 42, No. 5, 01.05.2007, p. 912-920.

Research output: Contribution to journalReview article

Goldberg, Jonathan L. ; Laughlin, Mary J. ; Pompili, Vincent J. / Umbilical cord blood stem cells : Implications for cardiovascular regenerative medicine. In: Journal of Molecular and Cellular Cardiology. 2007 ; Vol. 42, No. 5. pp. 912-920.
@article{8f7eed4b9b3747bc9d3d06e1194d6962,
title = "Umbilical cord blood stem cells: Implications for cardiovascular regenerative medicine",
abstract = "The treatment of cardiovascular disease has benefited from advances in pharmacologic and intravascular intervention reducing the morbidity and mortality associated with this disease. To address the need in managing clinically complex vascular disease with limited therapeutic options studies have focused on cellular therapy as a means to augment compensatory mechanisms and to potentially prevent escalation and advancement of disease. Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSC) and thus may be a potential source of cells for this type of therapy. UCB can be collected at no risk to the donor, is immediately available, has a wider availability of HLA phenotypes with a possible lower immune reactivity and does not provoke ethically charged debates. Moreover, stem cells isolated from patients with chronic disease have impairment of their reparative abilities thus limiting their therapeutic impact. The potential of UCB HSC in augmenting this process has been studied extensively both in vitro and in vivo and has shown a benefit in acute and chronic vascular ischemia. Although studies suggest efficacy with no obvious safety concerns the mechanism for this therapeutic effect is unknown.",
keywords = "Angiogenesis, Cardiovascular disease, Hematopoietic stem cell, Regenerative medicine, Umbilical cord blood",
author = "Goldberg, {Jonathan L.} and Laughlin, {Mary J.} and Pompili, {Vincent J.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1016/j.yjmcc.2007.02.005",
language = "English (US)",
volume = "42",
pages = "912--920",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Umbilical cord blood stem cells

T2 - Implications for cardiovascular regenerative medicine

AU - Goldberg, Jonathan L.

AU - Laughlin, Mary J.

AU - Pompili, Vincent J.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - The treatment of cardiovascular disease has benefited from advances in pharmacologic and intravascular intervention reducing the morbidity and mortality associated with this disease. To address the need in managing clinically complex vascular disease with limited therapeutic options studies have focused on cellular therapy as a means to augment compensatory mechanisms and to potentially prevent escalation and advancement of disease. Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSC) and thus may be a potential source of cells for this type of therapy. UCB can be collected at no risk to the donor, is immediately available, has a wider availability of HLA phenotypes with a possible lower immune reactivity and does not provoke ethically charged debates. Moreover, stem cells isolated from patients with chronic disease have impairment of their reparative abilities thus limiting their therapeutic impact. The potential of UCB HSC in augmenting this process has been studied extensively both in vitro and in vivo and has shown a benefit in acute and chronic vascular ischemia. Although studies suggest efficacy with no obvious safety concerns the mechanism for this therapeutic effect is unknown.

AB - The treatment of cardiovascular disease has benefited from advances in pharmacologic and intravascular intervention reducing the morbidity and mortality associated with this disease. To address the need in managing clinically complex vascular disease with limited therapeutic options studies have focused on cellular therapy as a means to augment compensatory mechanisms and to potentially prevent escalation and advancement of disease. Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSC) and thus may be a potential source of cells for this type of therapy. UCB can be collected at no risk to the donor, is immediately available, has a wider availability of HLA phenotypes with a possible lower immune reactivity and does not provoke ethically charged debates. Moreover, stem cells isolated from patients with chronic disease have impairment of their reparative abilities thus limiting their therapeutic impact. The potential of UCB HSC in augmenting this process has been studied extensively both in vitro and in vivo and has shown a benefit in acute and chronic vascular ischemia. Although studies suggest efficacy with no obvious safety concerns the mechanism for this therapeutic effect is unknown.

KW - Angiogenesis

KW - Cardiovascular disease

KW - Hematopoietic stem cell

KW - Regenerative medicine

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=34247624073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247624073&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2007.02.005

DO - 10.1016/j.yjmcc.2007.02.005

M3 - Review article

C2 - 17368666

AN - SCOPUS:34247624073

VL - 42

SP - 912

EP - 920

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 5

ER -